Published in J Cell Mol Med on November 19, 2013
Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy. J Cell Mol Med (2015) 0.80
In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy. Cancer Gene Ther (2016) 0.78
Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Mol Ther Methods Clin Dev (2016) 0.75
Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines. Cancer Gene Ther (2015) 0.75
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 10.60
The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol (1998) 5.50
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43
Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (1995) 3.53
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol (1993) 1.90
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 1.64
IL-12 deaths: explanation and a puzzle. Science (1995) 1.58
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res (2011) 1.33
Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res (2012) 1.32
Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood (1997) 1.18
Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck (2001) 1.09
GM-CSF-based fusion cytokines as ligands for immune modulation. J Immunol (2011) 0.96
The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors (2012) 0.93
IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med (2009) 0.91
Cytokine network: new targeted therapy for pancreatic cancer. Curr Pharm Des (2012) 0.90
Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One (2012) 0.90
Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood (1999) 0.82
Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res (2000) 0.81
Interleukin-12 inhibits the survival of human colon cancer stem cells in vitro and their tumor initiating capacity in mice. Cancer Lett (2012) 0.80
Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther (2012) 0.80
Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi (2002) 0.78
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med (2002) 3.24
Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet (2004) 2.96
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res (2009) 2.79
The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.71
RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev (2005) 2.59
iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science (2012) 2.14
Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol (2003) 2.12
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med (2011) 2.04
Acquisition of a multifunctional IgA+ plasma cell phenotype in the gut. Nature (2011) 2.04
Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation (2007) 2.03
Involvement of mammalian Mus81 in genome integrity and tumor suppression. Science (2004) 2.03
Hematopoietic stem cell responsiveness to exogenous signals is limited by caspase-3. Cell Stem Cell (2008) 1.94
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther (2007) 1.91
IL-7 does not prevent pro-B/pre-B cell maturation to the immature/sIgM(+) stage. Eur J Immunol (2004) 1.90
Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res (2005) 1.77
Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest (2005) 1.76
Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest (2010) 1.75
Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity (2012) 1.75
ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci (2010) 1.49
Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol (2006) 1.45
Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res (2007) 1.40
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res (2006) 1.39
The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. Semin Immunol (2012) 1.38
Circulating hormones and estrous stage predict cellular and stromal remodeling in murine uterus. Reproduction (2007) 1.37
TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation (2004) 1.36
Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology (2008) 1.36
Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol (2006) 1.35
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35
Caspase-3 regulates cell cycle in B cells: a consequence of substrate specificity. Nat Immunol (2003) 1.34
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
IL-7: a key regulator of B lymphopoiesis. Semin Immunol (2005) 1.32
Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J (2008) 1.32
Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology (2005) 1.31
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med (2013) 1.30
The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci (2008) 1.28
Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A (2004) 1.25
Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci U S A (2006) 1.23
Clipping, shedding and RIPping keep immunity on cue. Trends Immunol (2008) 1.20
Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene (2003) 1.20
GATA-3 regulates the self-renewal of long-term hematopoietic stem cells. Nat Immunol (2013) 1.19
IL-21: an executor of B cell fate. J Immunol (2009) 1.18
Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev (2004) 1.18
Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum (2007) 1.16
Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci (2012) 1.13
Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost (2005) 1.12
Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development (2013) 1.11
Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J Biol Chem (2009) 1.10
Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am J Pathol (2009) 1.10
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol (2005) 1.08
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther (2008) 1.06
Isolation of cell surface proteins for mass spectrometry-based proteomics. Expert Rev Proteomics (2010) 1.05
A null mutation for tissue inhibitor of metalloproteinases-3 (Timp-3) impairs murine bronchiole branching morphogenesis. Dev Biol (2003) 1.04
Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology (2010) 1.03
Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism. J Virol (2011) 1.03
Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol (2006) 1.03
Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res (2002) 1.02
Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model. PLoS One (2011) 1.02
Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem (2010) 1.02
Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy (2011) 1.01
Lack of susceptibility of cells from patients with Fabry disease to productive infection with R5 human immunodeficiency virus. AIDS (2005) 1.00
A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. J Nucl Med (2010) 1.00
Tachykinins in the immune system. Curr Drug Targets (2006) 0.99
Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res (2008) 0.99
Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am J Pathol (2005) 0.98
Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem (2003) 0.98
In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res (2010) 0.97
Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation (2009) 0.97
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res (2012) 0.97
Cooperation between IL-7 and the pre-B cell receptor: a key to B cell selection. Semin Immunol (2002) 0.97
TIMP-3 recruits quiescent hematopoietic stem cells into active cell cycle and expands multipotent progenitor pool. Blood (2010) 0.97
H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer (2006) 0.96
Cbl-3-deficient mice exhibit normal epithelial development. Mol Cell Biol (2003) 0.95
On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging. Anal Chem (2014) 0.94
Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med (2013) 0.94
Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J (2006) 0.94
Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica (2012) 0.92
Mechanisms of selection mediated by interleukin-7, the preBCR, and hemokinin-1 during B-cell development. Immunol Rev (2004) 0.91
IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med (2009) 0.91
Proteolytic factors in exosomes. Proteomics (2013) 0.90
Unraveling metalloproteinase function in skeletal biology and disease using genetically altered mice. Biochim Biophys Acta (2009) 0.90
Spontaneous fibroblast-derived pericyte recruitment in a human tissue-engineered angiogenesis model in vitro. J Cell Physiol (2012) 0.89
17beta-estradiol enhances the response of plasmacytoid dendritic cell to CpG. PLoS One (2009) 0.89
Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells. Virology (2008) 0.88
Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Hum Gene Ther (2011) 0.88